Group 1 - The company, Guoke Tianceng Technology Co., Ltd., is issuing convertible bonds to raise funds for enhancing its core competitiveness and profitability in the infrared optoelectronic industry [10][11][12] - The total amount of the convertible bonds to be issued is not more than RMB 880 million, with each bond having a face value of RMB 100 [15][16] - The funds raised will be allocated to projects including the construction of non-refrigerated infrared detectors, near-infrared APD photodetector production lines, and mid-wave infrared semiconductor laser projects [16] Group 2 - The infrared optoelectronic industry is supported by national policies, with increasing applications in both defense and civilian sectors, leading to a growing market demand [10][11][12] - The company has established a strong market position in the infrared field, focusing on both refrigerated and non-refrigerated infrared detectors, and is expanding its production capacity to meet the rising demand [12][13] - The company aims to enhance its product structure and profitability by developing new products such as near-infrared APD photodetectors and mid-wave infrared semiconductor lasers [13][14]

Core Viewpoint - The company, Teemsun Technology Co., Ltd., is planning to issue convertible bonds to unspecified investors, aiming to raise up to RMB 880 million to enhance its production capacity and improve its core component supply capabilities [15][23]. Company Overview - Teemsun Technology Co., Ltd. specializes in the research, production, and sales of optoelectronic products, particularly in infrared thermal imaging, navigation, and remote sensing [4][3]. - The company has obtained a total of 80 patents, including 44 invention patents, 14 utility model patents, and 22 design patents, showcasing its commitment to technological innovation [4]. Financial Data - As of the end of 2024, the total assets of the company amounted to RMB 2.5198 billion, with total liabilities of RMB 671.26 million, resulting in total equity of RMB 1.8485 billion [5]. - The company reported a revenue of RMB 960.65 million for the year 2024, with a net profit of RMB 175.43 million, reflecting a significant increase from RMB 121.42 million in 2023 [5][6]. Business Risks - The company faces risks related to macroeconomic changes, particularly in the defense sector, which could impact demand for its products [8]. - There is a risk of technological obsolescence in the optoelectronic industry, necessitating continuous investment in research and development [8]. - The company is also exposed to risks associated with the production capacity of its self-developed T2SL detectors, which are still in the ramp-up phase [8]. Issuance Details - The convertible bonds will have a face value of RMB 100 each and a maturity period of six years [15]. - The issuance will prioritize existing shareholders, with any remaining bonds offered to institutional investors [15][24]. Management and Oversight - The underwriting and advisory roles are being handled by Guotai Junan Securities, with a commitment to adhere to regulatory standards and ensure the integrity of the issuance process [18][21].

Group 1 - Liu Pharmaceutical Group plans to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.70 yuan per share [1] - Dongshan Precision intends to invest up to 1 billion USD to build a high-end printed circuit board project to meet the long-term demand for high-end printed circuit boards in emerging scenarios such as AI [1] - Bomaike reported a net profit of 12.39 million yuan for the first half of the year, a year-on-year decline of 80.42% [2] Group 2 - Western Mining achieved a net profit of 1.869 billion yuan in the first half of the year, a year-on-year increase of 15% [2] - Fuliwang expects a net loss of approximately 17 million yuan for the first half of the year, a decrease of 137.12% compared to the same period last year [2] - Digital Certification anticipates a net loss of between 80 million and 96 million yuan for the first half of the year, compared to a loss of 29.25 million yuan in the same period last year [3] Group 3 - Shanghai Construction reported a net profit of 710 million yuan for the first half of the year, a year-on-year decrease of 14.04% [5] - Funneng Co. achieved a net profit of 1.337 billion yuan in the first half of the year, a year-on-year increase of 12.48% [6] - Tengda Construction's total contract amount for the first half of the year decreased by 17.55% year-on-year [7] Group 4 - Fudan Fuhua decided to terminate the public transfer of a 28% stake in a subsidiary due to the lack of a deposit from potential buyers [9] - Fulei Ant's subsidiary has decided to cease operations due to intense competition in the photovoltaic industry and ongoing losses [11] - Dongfang Ocean's subsidiary received a medical device registration certificate for a folic acid testing kit [14] Group 5 - Huayu Pharmaceutical's subsidiary received overseas listing approvals for several products [16] - Feima International received a performance commitment compensation of 437 million yuan from its controlling shareholder [16] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan [16] Group 6 - Anhui Construction won the bid for the S68 Jingde to Jixi Expressway project with an estimated total investment of 5.7 billion yuan [18] - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [19] - Kehui Co. plans to use up to 70 million yuan of idle funds for cash management [22] Group 7 - Biological Shares' subsidiary received a clinical trial approval for a cat mRNA vaccine, the first of its kind in China [23] - Ruipu Biological received a clinical trial approval for a pig mRNA vaccine, which is the first economic animal mRNA vaccine in China [24] - Nanjing New Hundred's major assets were judicially frozen due to liquidity debt crisis faced by its controlling shareholder [27] Group 8 - Changshu Bank plans to merge three village banks and establish branches, pending shareholder approval [28] - Yong'an Pharmaceutical plans to reduce its holdings by up to 2.6323 million shares [29] - Zhujiang Co. received approval from the Shanghai Stock Exchange for a stock issuance to specific targets [31] Group 9 - Sanyangma's subsidiary signed a 120 million yuan procurement contract for sensor products [33] - Jintou City Development plans to purchase a villa property for approximately 7.1854 million yuan [35] - Yuanli Co. intends to acquire 100% of Tongsheng Co. through a combination of cash and stock issuance [36] Group 10 - Xin'an Century's controlling shareholder plans to reduce holdings by up to 2.22% of the company's shares [36] - Fute Technology plans to raise up to 528 million yuan through a private placement for various projects [36] - Helen Piano's actual controller is set to change, with stock resuming trading [37] Group 11 - Weiergao expects a net profit increase of 12.55% to 30.87% for the first half of the year [38] - Saiwei Microelectronics plans to transfer up to 18% of its shares through an agreement [40] - Yongli Co. intends to acquire a 22.75% stake in a subsidiary [42] Group 12 - ST Xiachuang plans to publicly transfer a 20% stake in Guangdong Yuweiji [43] - Dema Technology's shareholders plan to transfer 778.84 million shares through an inquiry [45] - Zhongshi Technology's shareholders plan to reduce holdings by up to 2.86% of the company's shares [46] Group 13 - Wufang Optoelectronics' controlling shareholder plans to reduce holdings by up to 0.93% of the company's shares [48] - Fusenmei's chairman has been detained, temporarily unable to fulfill his duties [49] - Reliable Co.'s shareholders plan to reduce holdings by a total of up to 2.63% of the company's shares [51] Group 14 - Gao Neng Environment plans to repurchase shares worth between 100 million and 150 million yuan [53]

Core Points - The company received a notification from the Shenzhen Stock Exchange on July 24, 2025, regarding the acceptance of its application for issuing convertible bonds to unspecified investors [1] - The Shenzhen Stock Exchange has verified that the application documents are complete and has decided to accept the application [1] - The issuance is subject to further review by the Shenzhen Stock Exchange and requires approval from the China Securities Regulatory Commission before implementation [1] - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations based on the progress of this matter [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 证券代码：301571 证券简称：国科天成 公告编号：2025-042 国科天成科技股份有限公司 关于向不特定对象发行可转换公司债券申请获得深圳证券 交易所受理的公告 国科天成科技股份有限公司董事会 2025 年 7 月 25 日 国科天成科技股份有限公司(以下简称"公司")于 2025 年 7 月 24 日收到深圳证券交易所(以下简称"深交所")出具的《关于受理国 科天成科技股份有限公司向不特定对象发行可转换公司债券申请文 件的通知》(深证上审(2025)143 号)。深交所对公司报送的向不特定 对象发行可转换公司债券的申请文件进行了核对,认为申请文件齐备, 决定予以受理。 公司本次向不特定对象发行可转换公司债券事项尚需深交所审 核,并获得中国证券监督管理委员会(以下简称"证监会")作出同意 注册的决定后方可实施。公司本次向不特定对象发行可转换公司债券 的事项最终能否通过深交所审核并获得证监会作出同意注册的批复 及其时间尚存在不确定性。公司将根据该事项的进展情况,按照相关 法律法规规定和要求及时履行信息披露义务 ...

北京金杜（成都）律师事务所 关于国科天成科技股份有限公司 向不特定对象发行可转换公司债券 之 法律意见书 致：国科天成科技股份有限公司 北京金杜（成都）律师事务所（以下简称本所）接受国科天成科技股份有限 公司（以下简称发行人）委托，担任发行人本次向不特定对象发行可转换公司债 券（以下简称本次发行）的中国境内专项法律顾问。 本所根据《中华人民共和国证券法》（以下简称《证券法》）、《中华人民 共和国公司法》（以下简称《公司法》）、《上市公司证券发行注册管理办法》 （以下简称《注册管理办法》）《深圳证券交易所创业板股票上市规则》（以下 简称《创业板上市规则》）、《律师事务所从事证券法律业务管理办法》（以下 简称《证券法律业务管理办法》）、《律师事务所证券法律业务执业规则（试 行）》（以下简称《证券法律业务执业规则》）、《公开发行证券公司信息披露 的编报规则第 12 号——公开发行证券的法律意见书和律师工作报告》（以下简称 《编报规则第 12 号》）等中华人民共和国境内（以下简称中国境内，为本法律意 见书之目的，不包括中国香港特别行政区、中国澳门特别行政区和中国台湾省） 现行有效的法律、行政法规、规章和规范性文件和中 ...

保荐机构（主承销商） 二〇二五年七月 国科天成科技股份有限公司 发行保荐书 国泰海通证券股份有限公司 关于 国科天成科技股份有限公司 向不特定对象发行可转换公司债券 之 发行保荐书 关于国科天成科技股份有限公司 向不特定对象发行可转换公司债券之发行保荐书 国科天成科技股份有限公司（以下简称"国科天成""发行人""公司"或"上 市公司"）拟申请向不特定对象发行不超过 88,000.00 万元可转换公司债券，并已 聘请国泰海通证券股份有限公司（以下简称"国泰海通""保荐机构"）作为本次 证券发行的保荐机构。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《证券发行上市保荐业务管理办法》（以下简 称"《保荐管理办法》"）、《上市公司证券发行注册管理办法》（以下简称"《注册 管理办法》"）、《发行证券的公司信息披露内容与格式准则第 27 号——发行保荐 书和发行保荐工作报告》《保荐人尽职调查工作准则》等法律法规和中国证券监 督管理委员会（以下简称"中国证监会"）及深圳证券交易所的有关规定，保荐 机构及其保荐代表人诚实守信，勤勉尽责，严格按照依法制订的业务 ...

（申报稿） （中 国 （上 海 ）自 由贸 易 试验 区 商城 路 618 号） 国科天成科技股份有限公司 （北京市海淀区北清路 81 号一区 4 号楼 9 层 901 室） 向不特定对象发行可转换公司债券 募集说明书 股票简称：国科天成 股票代码：301571 重大事项提示 公司特别提示投资者对下列重大事项给予充分关注，并仔细阅读本募集说 明书中有关风险因素的章节。 保荐机构（主承销商） 二〇二五年七月 国科天成科技股份有限公司 募集说明书 发行人声明 中国证监会、深交所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责，由此变化引致的投资风险，由投资者自行负责。投资者自主判断 发行人的投资价值，自主作出投资决策，自行承担证券依法发行后因发行人经营 与收益变化或者证券价格变动引致的投资风险。 1-1-1 国科天成科技股份有限公司 募集说明书 一、关于本次可转债发 ...

国科天成科技股份有限公司 2021 年度、2022 年度及 2023 年度 审计报告 致同会计师事务所 (特殊普通合伙) 6-1-1 目 录 | 审计报告 | 1-5 | | --- | --- | | 合并资产负债表 | 1-2 | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并股东权益变动表 | 5-7 | | 公司资产负债表 | 8-9 | | 公司利润表 | 10 | | 公司现金流量表 | 11 | | 公司股东权益变动表 | 12-14 | | 财务报表附注 | 15-147 | 6-1-2 Thornton 审计报告 致同审字(2024)第 110A012602 号 国科天成科技股份有限公司全体股东: 一、审计意见 我们审计了国科天成科技股份有限公司(以下简称国科天成公司)财务 报表,包括 2021年 12月 31 目、2022年 12月 31 目、2023年 12月 31 日 的合并 及公司资产负债表,2021年度、2022年度、2023年度的合并及公司利润表、合 并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按 ...

国泰海通证券股份有限公司 关于 国科天成科技股份有限公司 向不特定对象发行可转换公司债券 之 上市保荐书 保荐机构（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年七月 | 第一节 | 本次证券发行基本情况 3 | | --- | --- | | | 一、发行人基本情况 3 | | | 二、本次发行情况 11 | | | 三、保荐代表人、项目协办人及项目组其他成员情况 12 | | | 四、保荐人与发行人的关联关系、保荐人及其保荐代表人是否存在可能影响 | | | 公正履行保荐职责情形的说明 13 | | 第二节 | 保荐人承诺事项 15 | | 第三节 | 保荐人对本次证券发行上市的保荐结论 17 | | | 一、本次发行履行了必要的决策程序 17 | | | 二、保荐人对本次证券上市的推荐结论 17 | | 第四节 | 保荐机构关于发行人持续督导工作的安排 18 | 声 明 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"或"保荐机 构"）及其保荐代表人已根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证 ...